"The U.S. Food and Drug Administration today allowed marketing in the U.S. of the first mass spectrometer system for automated identification of bacteria and yeasts that are known to cause serious illness in humans. The VITEK MS can identify 193 d"...
Lamprene (clofazimine) is indicated in the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. Lamprene (clofazimine) has not been demonstrated to be effective in the treatment of other leprosy-associated inflammatory reactions.
DOSAGE AND ADMINISTRATION
Lamprene (clofazimine) should be taken with meals.
Lamprene (clofazimine) should be used preferably in combination with one or more other antileprosy agents to prevent the emergence of drug resistance.
For the treatment of proven dapsone-resistant leprosy, Lamprene (clofazimine) should be given at a dosage of 100 mg daily in combination with one or more other antileprosy drugs for 3 years, followed by monotherapy with 100 mg of Lamprene (clofazimine) daily. Clinical improvement usually can be detected between the first and third months of treatment and is usually clearly evident by the sixth month.
For dapsone-sensitive multibacillary leprosy, a combination therapy with two other antileprosy drugs is recommended. The triple-drug regimen should be given for at least 2 years and continued, if possible, until negative skin smears are obtained. At this time, monotherapy with an appropriate antileprosy drug can be instituted.
The treatment of erythema nodosum leprosum reactions depends on the severity of symptoms. In general, the basic antileprosy treatment should be continued, and if nerve injury or skin ulceration is threatened, corticosteroids should be given. Where prolonged corticosteroid therapy becomes necessary, Lamprene (clofazimine) administered at dosages of 100 to 200 mg daily for up to 3 months may be useful in eliminating or reducing corticosteroid requirements. Dosages above 200 mg daily are not recommended, and the dosage should be tapered to 100 mg daily as quickly as possible after the reactive episode is controlled. The patient must remain under medical surveillance.
For advice about combination drug regimens, contact the USPHS Gillis W. Long Hansen's Disease Center, Carville, LA (504-642-7771).
Soft Gelatin Capsules 50 mg–brown, spherical
Bottles of 100...........................NDC 0028-0108-01
Store below 30ºC (86ºF). Protect from moisture.
Dispense in tight container (USP).
Distributed by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. Rev 9/98. FDA rev date: 6/11/2003
Last reviewed on RxList: 11/5/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Lamprene Information
- Lamprene Drug Interactions Center: clofazimine oral
- Lamprene Side Effects Center
- Lamprene FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.